Protein Tyrosine Kinases
-
PHA-665752
Catalog No. A10713 -
JNJ-38877605
Catalog No. A10493 -
BMS-777607
Catalog No. A10153 c-Met 抑制剂BMS-777607是一种MET酪氨酸激酶抑制剂,与c-Met蛋白或HGFR结合,可防止HGF结合并破坏MET信号通路。 了解更多 -
PF-04217903
Catalog No. A10711 c-Met 抑制剂PF-04217903是一种选择性的,ATP竞争性c-Met抑制剂,在A549细胞中IC50为4.8 nM,对致癌基因突变型敏感(对Y1230C突变型没有活性)。 了解更多 -
AMG 208
Catalog No. A10063 -
AMG-458
Catalog No. A11055 -
EMD-1214063
Catalog No. A11257 c-Met 抑制剂EMD-1214063是MET酪氨酸激酶的抑制剂,IC50为4 nM,作用于c-Met比作用于IRAK4, TrkA, Axl, IRAK1和Mer选择性高200倍以上。具有潜在的抗肿瘤活性。它与MET酪氨酸激酶结合并破坏MET信号转导途径,这可能在过表达该激酶的肿瘤细胞中诱导凋亡。 了解更多 -
Volitinib (Savolitinib, AZD-6094)
Catalog No. A14419 -
c-Met inhibitor 1
Catalog No. A15049 -
Glumetinib (SCC-244)
Catalog No. A18328 c-Met inhibitorGlumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin. 了解更多 -
JNJ-38877618
Catalog No. A18325 c-Met inhibitorJNJ-38877618 is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. 了解更多 -
BMS 777607
Catalog No. A21638 c-Met/Axl/Ron/Tyro3 inhibitorBMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. 了解更多 -
LY2801653 dihydrochloride
Catalog No. A15150 -
PF-04217903 methanesulfonate
Catalog No. A15208 c-Met 抑制剂PF-04217903 methanesulfonate是一种选择性ATP竞争性c-Met抑制剂,IC50为4.8 nM,易致癌突变(对Y1230C突变体无活性)。 了解更多 -
LY2801653 (Merestinib)
Catalog No. A12557 -
c-Met inhibitor 2
Catalog No. A16256 -
Glesatinib hydrochloride
Catalog No. A16257 -
ARQ 197 (Tivantinib)
Catalog No. A11087 c-Met 抑制剂ARQ-197是c-Met受体酪氨酸激酶的选择性抑制剂, 在无细胞试验中Ki为0.355 μM,对Ron几乎没有作用活性,对EGFR, InsR, PDGFRα和FGFR1/4没有抑制作用。 了解更多 -
PF-2341066 (Crizotinib)
Catalog No. A10712 ALK/ c-Met 抑制剂PF-2341066 (Crizotinib)是c-Met激酶和NPM-ALK的抑制剂。PF-2341066抑制ALK阳性ALCL细胞中的细胞增殖(IC50 = 30 nM)。 了解更多 -
R406 besylate
Catalog No. A10769 Syk 抑制剂R406 besylate是一种口服酪氨酸激酶抑制剂,IC50为41 nM。对Syk抑制作用强,但是不抑制Lyn,对Flt3的作用比对Syk低5倍。 了解更多 -
R406 (Tamatinib)
Catalog No. A10770 Syk 抑制剂R406 (Tamatinib)是一种口服酪氨酸激酶抑制剂,IC50为41 nM。对Syk抑制作用强,但是不抑制Lyn,对Flt3的作用比对Syk低5倍。 了解更多 -
Tandutinib (MLN518)
Catalog No. A10887 -
TG-101348 (Fedratinib, SAR302503)
Catalog No. A11082 JAK2/FLT3 抑制剂TG-101348 (Fedratinib,SAR302503)是Janus相关激酶2的口服生物利用型,ATP竞争性和选择性抑制剂,在无细胞试验中IC50为3 nM,作用于JAK2比作用于JAK1和JAK3选择性高35和334倍,具有潜在的抗肿瘤活性。 了解更多 -
TCS 359
Catalog No. A12427 -
AST 487
Catalog No. A15003 -
SB1317 (TG02)
Catalog No. A13454 CDK/JAK2/FLT3 抑制剂SB1317是细胞周期蛋白依赖性激酶(CDKs)、类FMS酪氨酸激酶-3(FLT3)和Janus激酶2(JAK2)的有效抑制剂,CDK2、JAK2和FLT3的IC50值分别为13nM、56nM和73nM。 了解更多 -
Gilteritinib hemifumarate
Catalog No. A18235 FLT3/AXL inhibitorGilteritinib hemifumarate is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. 了解更多 -
TG-02 (SB1317)
Catalog No. A11962 -
G-749
Catalog No. A14214 -
Gilteritinib (ASP2215)
Catalog No. A14411 FLT3/Axl 抑制剂Gilteritinib (ASP2215)是一种有效的FLT3/AXL抑制剂,对具有AML突变或FLT3-ITD和FLT3-D835的AML具有有效的抗白血病活性。 了解更多 -
AMG-925
Catalog No. A14025 -
SU5614
Catalog No. A15548 -
FLT3-IN-1
Catalog No. A16249 -
Pacritinib (SB1518)
Catalog No. A12694 JAK2/FLT3 抑制剂Pacritinib (SB1518)是Janus激酶2(JAK2)和JAK2突变体JAK2V617F的口服生物利用抑制剂,无细胞试验中IC50分别为23和22 nM,具有潜在的抗肿瘤活性。Pacritinib与JAK2竞争ATP结合,这可能导致抑制JAK2活化,抑制JAK-STAT信号传导途径以及半胱天冬酶依赖性凋亡。 了解更多